|1.||Huber, Brigitte T: 7 articles (12/2009 - 07/2003)|
|2.||Drouin, Elise E: 6 articles (02/2011 - 02/2003)|
|3.||Steere, Allen C: 6 articles (02/2011 - 02/2003)|
|4.||Barrett, P Noel: 5 articles (11/2014 - 02/2011)|
|5.||Portsmouth, Daniel: 4 articles (11/2014 - 01/2013)|
|6.||Livey, Ian: 4 articles (11/2014 - 02/2011)|
|7.||Crowe, Brian A: 4 articles (11/2014 - 02/2011)|
|8.||Nepom, Gerald T: 4 articles (01/2008 - 02/2003)|
|9.||O'Rourke, Maria: 3 articles (11/2014 - 02/2011)|
|10.||Koide, Shohei: 3 articles (02/2012 - 12/2002)|
|1.||Lyme Disease (Disease, Lyme)
06/01/1995 - "In vivo vaccination studies supported the in vitro findings, confirming that vaccination with a single OspA protein does not provide complete protection against challenge with all Lyme disease spirochetes. "
07/01/1998 - "Compared with placebo, the OspA vaccine significantly reduced the frequency of Lyme disease during the 2-year study period (P < 0.04, one-tailed Fisher's exact test). "
07/23/1998 - "In this study, OspA vaccine was safe and effective in the prevention of Lyme disease."
09/01/2013 - "A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies."
01/01/2003 - "An efficacy trial of an outer-surface protein A (OspA) Lyme disease vaccine demonstrated tolerability and efficacy against laboratory-confirmed Lyme disease after a primary series of 3 doses at 0, 1, and 12 months. "
01/01/2015 - "The recombinant outer surface protein A (rOspA) vaccine for dogs is highly effective in preventing new seropositive cases of Borrelia burgdoferi infection over a five-year period in dogs living in an endemic area. "
04/01/2013 - "We assessed the efficacy of an easily distributable oral bait vaccine based on the immunogenic outer surface protein A (OspA) to protect uninfected mice from infection and to reduce transmission from previously infected white-footed mice, an important reservoir host of B. "
03/01/1997 - "Data presented here demonstrate a significant correlation between antibody to an epitope on outer surface protein A (OspA) and protection against infection with Borrelia burgdorferi in canines and mice. "
05/01/2006 - "In this study, 746 questing Ixodes (I.) ricinus ticks from eastern Slovakia and 187 ticks from southern Poland were investigated for infection with Borrelia (B.) burgdorferi sensu lato and different outer surface protein A (OspA) types by an improved restriction fragment length polymorphism (RFLP) analysis of the ospA gene. "
11/04/2015 - "Immunization with the outer surface protein A (OspA) can prevent infection and the C-terminal part of OspA is sufficient for protection against infection transmitted by Ixodes ticks. "
|3.||Bites and Stings (Sting)
10/01/1997 - "Immunization with a polyvalent OspA vaccine protects mice against Ixodes ricinus tick bites infected by Borrelia burgdorferi ss, Borrelia garinii and Borrelia afzelii."
06/01/2005 - "A recombinant outer surface protein A (OspA) vaccine was approximately 80% effective in clinical trials in the United States, and a single 200 mg dose of doxycycline given within 72 hours of an I. scapularis tick bite, was shown to be 87% effective. "
02/01/2011 - "burgdorferi outer-surface protein A (OspA₁₆₃₋₁₇₅), and cellular and humoral immune responses to OspA are greater in patients with antibiotic-refractory arthritis than in those with antibiotic-responsive arthritis. "
08/01/2007 - "Molecular mimicry between OspA (outer surface protein A) and adhesion molecule LFA-1alpha seems to be responsible for chronic arthritis."
04/15/2001 - "A marked Ab and T cell response to BB: outer surface protein A (OspA) often develops during prolonged episodes of arthritis. "
12/01/2000 - "Outer surface protein A and arthritis in hamsters."
02/01/2000 - "Here we provide direct evidence that a major surface protein, outer surface protein A (OspA), can induce arthritis. "
10/01/2001 - "Our analysis of the asymptomatic infections diagnosed serologically in a recent OspA vaccine trial conducted in the United States (N Engl J Med 1998;339: 209-215), suggests that the natural history of this event is more benign than that reported for untreated patients with erythema migrans (Ann Intern Med 1987;107: 725-731). "
|10.||T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)